DPT Laboratories, Confab Announce Integration
News Oct 17, 2013
DPT Laboratories has announced the integration of the organizations under the leadership of Paul Johnson, Group President and COO.
Both DPT and Confab are owned by Renaissance Acquisition Holdings, LLC, a portfolio company of RoundTable Healthcare Partners, and represent its CDMO holdings.
The integration includes a re-branding and new logo for Confab, identifying it as a DPT company. A primary focus of the integration is for DPT’s established sales and marketing team to introduce Confab’s specialized expertise in complex solid, semi-solid and liquid dosage forms to new pharmaceutical industry clients, especially in the U.S. market.
The management teams for both companies will remain in place, with Confab development and manufacturing continuing to operate under the direction of President and General Manager Nathalie Brisson.
“Confab is one of the most-respected pharmaceutical outsourcing organizations in Canada, with more than 30 years’ experience in manufacturing, packaging and analyzing a wide range of projects for both large and small pharmaceutical companies,” said Johnson.
“The integration will provide our sales team with complimentary manufacturing capabilities and a broader range of services to offer to our customers,” he added. “At the same time, the increased marketing support will leverage the continued investment Confab has made in infrastructure and capabilities, paying dividends in new client development and increased sales growth.”
Confab has 350 employees and a 140,000-square-foot, cGMP-compliant turnkey facility, which is licensed by the Health Canada Therapeutic Products Directorate, as well as the United States Food and Drug Administration.
“DPT’s sales and marketing team has a proven track record for building client relationships and driving growth,” said Brisson. “For our team at Confab, this will mean broader recognition of our capabilities and services, access to new markets and increased opportunities for growth.”
DPT, the industry leader for semi-solids and liquids, has research and development as well as manufacturing facilities in San Antonio, TX, as well as in Lakewood, N.J., where it is expanding its presence in the sterile and specialty products markets.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018